1 false false false false false false false false false false true false false false false false false No description of principal activity 2023-02-01 Sage Accounts Production Advanced 2023 - FRS102_2023 xbrli:pure xbrli:shares iso4217:GBP 13843848 2023-02-01 2024-01-31 13843848 2024-01-31 13843848 2023-01-31 13843848 2022-01-12 2023-01-31 13843848 2023-01-31 13843848 2022-01-11 13843848 bus:LeadAgentIfApplicable 2023-02-01 2024-01-31 13843848 bus:Director1 2023-02-01 2024-01-31 13843848 core:WithinOneYear 2024-01-31 13843848 core:WithinOneYear 2023-01-31 13843848 core:ShareCapital 2024-01-31 13843848 core:ShareCapital 2023-01-31 13843848 core:RetainedEarningsAccumulatedLosses 2024-01-31 13843848 core:RetainedEarningsAccumulatedLosses 2023-01-31 13843848 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-01-31 13843848 core:CostValuation core:Non-currentFinancialInstruments 2024-01-31 13843848 core:Non-currentFinancialInstruments 2024-01-31 13843848 bus:SmallEntities 2023-02-01 2024-01-31 13843848 bus:AuditExemptWithAccountantsReport 2023-02-01 2024-01-31 13843848 bus:SmallCompaniesRegimeForAccounts 2023-02-01 2024-01-31 13843848 bus:PrivateLimitedCompanyLtd 2023-02-01 2024-01-31 13843848 bus:AbridgedAccounts 2023-02-01 2024-01-31 13843848 core:ComputerEquipment 2023-02-01 2024-01-31
STATEMENT OF CONSENT TO PREPARE ABRIDGED FINANCIAL STATEMENTS
All of the members of Mak Orthopaedics Ltd have consented to the preparation of the abridged statement of comprehensive income and the abridged statement of financial position for the year ending 31 January 2024 in accordance with Section 444(2A) of the Companies Act 2006.
COMPANY REGISTRATION NUMBER: 13843848
MAK ORTHOPAEDICS LTD
FILLETED UNAUDITED ABRIDGED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 January 2024
MAK ORTHOPAEDICS LTD
REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY ABRIDGED FINANCIAL STATEMENTS OF MAK ORTHOPAEDICS LTD
YEAR ENDED 31 JANUARY 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the abridged financial statements of Mak Orthopaedics Ltd for the year ended 31 January 2024, which comprise the abridged statement of financial position and the related notes from the company's accounting records and from information and explanations you have given us. As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at www.accaglobal.com/en/member/professional-standards/rules-standards/acca-rulebook.html. Our work has been undertaken in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at www.accaglobal.com/content/dam/ACCA_Global/Technical/fact/technical-factsheet-163.pdf.
LANGARD LIFFORD HALL LIMITED Accountants and Registered Auditors
Lifford Hall Lifford Lane Kings Norton Birmingham B30 3JN
19 August 2024
MAK ORTHOPAEDICS LTD
ABRIDGED STATEMENT OF FINANCIAL POSITION
31 January 2024
2024
2023
Note
£
£
£
£
Fixed assets
Tangible assets
5
2,237
1,797
Investments
6
25,000
------------
------------
27,237
1,797
Current assets
Cash at bank and in hand
17,190
15,029
Creditors: amounts falling due within one year
17,486
6,799
------------
------------
Net current (liabilities)/assets
( 296)
8,230
------------
------------
Total assets less current liabilities
26,941
10,027
------------
------------
Net assets
26,941
10,027
------------
------------
Capital and reserves
Called up share capital
10
10
Profit and loss account
26,931
10,017
------------
------------
Shareholders funds
26,941
10,027
------------
------------
These abridged financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the abridged statement of comprehensive income has not been delivered.
For the year ending 31 January 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its abridged financial statements for the year in question in accordance with section 476 ;
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of abridged financial statements .
MAK ORTHOPAEDICS LTD
ABRIDGED STATEMENT OF FINANCIAL POSITION (continued)
31 January 2024
These abridged financial statements were approved by the board of directors and authorised for issue on 19 August 2024 , and are signed on behalf of the board by:
M A Kemp
Director
Company registration number: 13843848
MAK ORTHOPAEDICS LTD
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
YEAR ENDED 31 JANUARY 2024
1. General Information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Lifford Hall Lifford Lane, Kings Norton, Birmingham, B30 3JN, England.
2. Statement of Compliance
These abridged financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting Policies
Basis of preparation
The abridged financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The abridged financial statements are prepared in sterling, which is the functional currency of the entity.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods supplied and services rendered, stated net of discounts and of Value Added Tax.
Income tax
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively.
Tangible assets
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
Equipment
-
25% reducing balance
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably without undue cost or effort, the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financial instruments are classified and accounted for, according to the substance of the contractual arrangement, as either financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
4. Employee Numbers
The average number of persons employed by the company during the year amounted to 1 (2023: 1 ).
5. Tangible Assets
£
Cost
At 1 February 2023
2,111
Additions
899
------------
At 31 January 2024
3,010
------------
Depreciation
At 1 February 2023
314
Charge for the year
459
------------
At 31 January 2024
773
------------
Carrying amount
At 31 January 2024
2,237
------------
At 31 January 2023
1,797
------------
6. Investments
£
Cost
At 1 February 2023
Additions
25,000
------------
At 31 January 2024
25,000
------------
Impairment
At 1 February 2023 and 31 January 2024
------------
Carrying amount
At 31 January 2024
25,000
------------
7. Director's Advances, Credits and Guarantees
Amounts owed to the director at the balance sheet date are included in creditors and totalled £12,459 (2023 £3,816).